Fennec Pharmaceuticals, Inc. FENC 深 滬
交易中 07-17 10:35:35 美东时间
8.875
-0.045
-0.50%
華盛通- 最 高8.9625
- 今 開8.94
- 成交量 2175股
- 最 低 8.875
- 昨 收 8.92
- 總市值 2.45亿
- 52周最高 9.30
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 3.96
- 委 比 -93.17%
- 總股本 2761.87万
- 歷史最高 14.986
- 量 比 0.23
- 振 幅 0.98%
- 歷史最低 3.255
- 每 手 1
- 風險率 2.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fennec Pharmaceuticals Approves Proposals at Shareholder Meeting
The latest update is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). On June 3,...
06-04 05:03
Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Inc. announced that all nominated directors were elected at the Annual General and Special Meeting of Shareholders held on June 3, 2025, in New York. Voting results showed strong support for each nominee, with Dr. Khalid Islam receiving 97.84% approval and Dr. Jodi Cook garnering 93.62%. Shareholders also approved the appointment of Haskell & White LLP as auditors (99.64%), the named executive officers' compensation (85.50%...
06-03 20:31
京东物流x芬驰合作再升级，温州时尚行业专仓开仓！
随着618年中大促的脚步临近，电商行业进入全年最关键的备战期。近日，国内眼镜电商头部企业芬驰眼镜与京东物流深化合作，温州时尚行业专仓暨芬驰眼镜仓正式开仓。这座坐...
05-23 19:26
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $13
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $12 to $13.
05-15 01:48
Fennec Pharmaceuticals Q1 EPS $(0.04) Beats $(0.09) Estimate, Sales $8.75M Beat $8.18M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 109.76 percent decrease over earnings of $0.41 per
05-13 18:05
Earnings Scheduled For May 13, 2025
Companies Reporting Before The Bell • Endeavour Silver (NYSE:EXK) is estimated ...
05-13 16:32
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
03-12 11:01
